1 day ago · Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna …

1 day ago · Goldman forecast RSV vaccine revenue of $1.5 billion, which is at the lowest end of the $1.5 billion to $2.5 billion range produced by Moderna. The Goldman team also says …

1 day ago · Moderna’s guidance for fiscal year 2025 (FY2%) revenue from the respiratory vaccine business is between $1.5 billion and $2.5 billion, aligning with Goldman’s estimate of $1.5 billion.

2 days ago · Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (XTRA:0QF) from Buy to Neutral. As of January 28, 2025, the average one-year …

Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its …

Moderna stock was losing ground as investors appeared increasingly doubtful its vaccine sales will be able to lift the beaten-down share price. Goldman Sachs cut its recommendation on the …

1 day ago · Analyst Salveen Richter downgraded shares of the biotech company from neutral to buy and significantly lowered her price target.

1 day ago · Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting …

1 day ago · Goldman Sachs downgraded Moderna to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance represents the second in a series of …

2 days ago · Moderna (NASDAQ:MRNA - Get Free Report) had its price objective lowered by stock analysts at The Goldman Sachs Group from $112.00 to $99.00 in a research note …